KYMR Kymera Therapeutics, Inc.
$114.96▼ -1.74%
Healthcare
Other
After hours
$114.96▲ +0.00%
Sep 11, 7:30 PM ET
Volume 574.2K
Avg Volume (10D) 633.1K
Key Metrics & Fundamentals
Market Cap
$9.46B
P/E Ratio
–
Div Yield
–%
52W Range
45.84 - 130.05
% vs 50 MA
0.49%
% vs 200 MA
27.58%
RSI-14
47.3
MACD Histogram
-1.0900
Beta (1Y vs SPY)
0.81
Free Cash Flow
-$54.54M
Gross Rev
$65.00M
Gross Profit
$65.00M
EBITDA
-$59.10M
COGS
–
Operating Exp
$140.61M
Operating Income
-$75.61M
EBIT
-$75.61M
Pretax Income
-$61.21M
Net Income
-$61.21M
EPS (Diluted)
-0.62
Price & Volume History
Loading chart…
Recent News
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Zacks · Sep 4, 2026 3:30 PM
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
Zacks · Sep 3, 2026 3:50 PM
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire · Sep 2, 2026 8:01 PM
Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says
MT Newswires · Sep 2, 2026 2:59 PM
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
GlobeNewswire · Sep 1, 2026 11:00 AM
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 12, 2026 5:14 PM
Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says
MT Newswires · Aug 10, 2026 4:44 PM
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
Zacks · Aug 6, 2026 6:52 PM
Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR)
Simply Wall St. · Aug 6, 2026 7:15 AM
Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 5, 2026 10:01 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See KYMR's money flow as a full page
Social Sentiment
No Reddit posts found for KYMR.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.